AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06268457 — intervention group
Intervention type: PROCEDURE
Intervention: Chemoembolization with Doxorubicin
Description: * Identification of the main vessels afferent to the metastasis to be treated.~* Selective and super-selective catheterization of pathological arterial branches, responsible for the blood supply to the neoplasm, through the use of micro-catheters.~* Injection of embolizing material (hydrogel microspheres with doxorubicin)~* Control of technical success: the embolization will be followed by diagnostic arteriography that will evaluate the success of the procedure (occlusion of more than 90 percent of the pathologic vasculature).
Study NCT04857333 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT scan
Description: For patients with low-risk pulmonary nodules, follow-up CT scan is recommended
Study NCT04857333 — intervention group
Intervention type: DRUG
Intervention: Antibiotics
Description: For pulmonary nodules with features of infectious disease, antibiotics is recommended
Study NCT04857333 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical Resection
Description: For persistent high-risk pulmonary nodules, surgical resection is recommended
Study NCT05502055 — intervention group
Intervention type: OTHER
Intervention: Individual interviews
Description: One on One interviews by Zoom video conferencing, \< 2 hours in duration
Study NCT05502055 — intervention group
Intervention type: OTHER
Intervention: Focus Groups
Description: Focus Groups discussions by Zoom video conferencing, \< 2 hours in duration
Study NCT05502055 — intervention group
Intervention type: OTHER
Intervention: National Survey
Description: Survey conducted online and distributed nationally
Study NCT04808908 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803, provided by ImmunityBio., Inc. will be administered subcutaneously at a dose 6 mcg/kg on Days 0, 21, and 42 (with a dosing window of up to 14 days post the planned dosing day)
Study NCT05230654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Fosaprepitant: 4 mg/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO. When used with fosaprepitant, dexamethasone dose was halved.
Study NCT05230654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(normal saline)
Description: Placebo(normal saline): 4 ml/kg IV Granisetron+dexamethasone: granisetron:40mcg/kg, IV ; dexamethasone : S\<0.6m2, 2 mg/dose, q12h IV/PO; S>0.6m2, 4 mg/dose, q12h , IV/PO.
Study NCT05248399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Group Problem Solving
Description: The COVID-19 Group Problem Solving component incorporates popular education activities aimed at: developing social cohesion among LDLs; building awareness about COVID-19 risks and protective behaviors; and developing a plan of action to reduce theirs and their peers' risk for COVID-19 transmission. The intervention will be developed to take place over a \~30-45-minute period in order to fit within the corner context of LDLs waiting for employment, and will be delivered by promoters from our team and the community partner agency, Fe \& Justicia Workers Center. Following the completion of the intervention, a health promoter will be trained as a navigator assist participants who wish to get vaccinated by providing them with information about near-by vaccination sites that they can visit to get vaccinated. If needed, the promotor will assist them with making their vaccine appointment.
Study NCT05248399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: The standard of care consists of the distribution of brochures containing COVID-19 prevention information.
Study NCT05248399 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard of care consists of the distribution of brochures containing COVID-19 prevention information.
Study NCT06482645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Perilesional/regional systematic biopsy
Description: The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. For each predefined mpMRI suspicious lesion, urologists obtained nine cores at 5-mm intervals within and around the region of interest (penumbra). The location of these nine cores depended on the shape and location of the suspicious lesion.
Study NCT06482645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combination of systematic biopsy and targeted biopsy
Description: The biopsy procedure was conducted by a highly skilled and experienced urologist who specializes in performing prostate biopsies. Prophylactic antibiotics were routinely used both before and one day prior to scheduled surgery. Each patient was placed in the left lateral position or lithotomy position. The ultrasound equipment used included a color Doppler ultrasound diagnostic instrument (Hitachi HiVision, Philips Epiq 7), transrectal probes, and corresponding puncture needle guns. Color Doppler examination was performed from the base to the apex. Three to five targeted biopsies from the lesion were performed within and around the predefined mpMRI suspicious lesion, followed by fore-zone 12-core biopsy.
Study NCT05993754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention
Description: The intervention consists of six main elements:~Correction of sensory deficits: Before surgery, the use of glasses, hearing aids and/or removable dental prostheses will be allowed, which will be removed before starting anesthesia in the emergency room. After surgery, they will be delivered back to the user.~Reorientation: In the postoperative period, the person will be informed where they are and the visit of the companion will be coordinated.~Early mobilization: A protocolized mobilization routine will be applied according to pain, state of consciousness, risk of thromboembolic disease and risk of falls.~Environmental management: You will be shown the time on a clock, it will reinforce the idea of the place where you are and that you can count on the team in case you need assistance.~Sleep protocol: The elderly person who does not want or cannot perform the mobilization routine, non-pharmacological sleep will be privileged.~Reduction of anticholinergic drugs
Study NCT05814770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone
Description: The participants were randomized in an equal ratio to receive finerenone 10 mg once daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to finerenone 20 mg once daily. If BP > 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
Study NCT05814770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: The participants were randomized in an equal ratio to receive spironolactone 20 mg twice daily. Patients received the initial dose of study drug for the first 4 weeks of randomized treatment period. Thereafter, the dose of study medication was not changed for patients with adequate BP control. For patients not meeting BP \< 140/90 mmHg at week 4, the dose of study medication was increased to spironolactone 40 mg twice daily. If BP > 160/110 mmHg at the time of 8 weeks follow-up, nifedipine 30mg once day was added.
Study NCT05588362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fitz Frames 3-D Printed Glasses
Description: The intervention group will order glasses directly in the office following their exam and consent using an iPad with the help of the research assistant. The iPad will be e-connected to a 3D printed glasses manufacturer (Fitz Frames) through their application, allowing the child (with assistance from the doctor or research assistant) to take various measurements in real time. Sixteen different measurements will be taken including interpupillary distance, face length, face width, and temple measures. The child will be able to choose frame style and order it directly from the manufacturer immediately following the exam. Glasses will be shipped directly to the patient's home (shipping address will be input to the app by the family).
Study NCT06029166 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Insertable subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®)
Description: Implantation of a subcutaneous cardiac monitor (BIOMONITOR IIIm®, Biotronik®) before beginning the Bruton's tyrosine kinase inhibitor treatment.
Study NCT04968925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE Oasys 1-Day
Description: TEST
Study NCT05400720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentoring
Description: At least one meeting between the mentor and mentee will occur to share experiences and see if the mentee would like to continue meeting with a mentor
Study NCT05377710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sinus lift with lateral approach
Description: Maxillary sinus floor augmentation or sinus lift is a surgical procedure, which provides a solution to the problem of sinus bone loss (too thin), and thus increases the thickness of the bone for immediate or subsequent implant placement in the premolars and molars (4). It consists of the elevation of the sinus mucosa that lines the maxillary sinus. The space thus freed will be filled with a bone filling material
Study NCT04968925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision 1
Description: CONTROL
Study NCT05534555 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FebriDx
Description: Testing of finger-prick blood sample using FebriDx
Study NCT05023798 — intervention group
Intervention type: DEVICE
Intervention: ATD (device test)
Description: Medical device test (no intervention)
Study NCT04961840 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT04994132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT04994132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study NCT04994132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy
Study NCT04994132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT04994132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT04994132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV or PO
Study NCT04994132 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dactinomycin
Description: Given IV
Study NCT04257695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TapPro
Description: Manualized intervention administered by a clinician to facilitate opioid tapering during clinical visits.
Study NCT05212987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FCN-098
Description: FCN-098 will be given orally in ascending doses starting at 40 mg Q12h until the maximum tolerated dose or recommended dose is reached.
Study NCT04994132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05428696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2080
Description: Powder-in-capsule
Study NCT04722224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation
Description: The reabilitAR program includes the self-management educational program Living Well with COPD. The exercise training will include endurance, resistance/strength, flexibility and balance training.
Study NCT05758142 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium Chloride
Description: Oral administration of potassium chloride tablets
Study NCT05758142 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of inert placebo tablets
Study NCT06536855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil 9
Description: GARDASIL 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.~GARDASIL 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.
Study NCT05572632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Wellness
Description: COPD Wellness consists of 10 weekly sessions led by the COPD Wellness Coach. The intervention was designed to be portable, rely on little equipment, and require limited space (\~300sqft). The curriculum was iteratively developed with patient input and builds behavioral capability and self-efficacy through 30 minutes blocks of disease education and self-management skill building, exercise training, and social support.
Study NCT05572632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COPD Wellness Plus+
Description: Couples COPD Wellness with the ZSFG Health Advocates Program. The HA will help the participant prioritize identified needs and, using an algorithm informed approach to connect the individual to the needed resource, this includes providing referrals to outside social or legal service agencies, help with applications for social benefits, or other services. The HA will use a checklist to track activities including review and prioritization of needs, referrals or resources provided, and contacts/contact attempts.
Study NCT05572632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Includes access to comprehensive primary care services that is standardized across the SFHN. Participants randomized to the usual care arm will be offered referral to the Better Breathing Program that is part of SFHN standard care for COPD. At end of study enrollment, usual care participants will be offered the COPD Wellness intervention.
Study NCT06541080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Shallow Whole Genome Sequencing (sWGS)-GIPXplore
Description: GIPXplore will be used to mine shallow whole genome sequencing cell free DNA data for identification of signatures.
Study NCT06541080 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: methylation-sensitive restriction enzymes (MSRE)-Single-molecule molecular inversion probes (smMIP)-seq assay
Description: Aberrant methylation in ccfDNA will be analyzed using the novel, highly sensitive MSRE-smMIP-seq technology.
Study NCT04961580 — intervention group
Intervention type: DRUG
Intervention: Ceftazidime Avitbatan Sodium
Description: For 6-18 years children, 62.5 mg/kg/once，q8h ; 3-6 months of age 50 mg/kg/ once,q8h, intravenous administration for 2 hours, daily dose is not more than 2.5g, children will be administrated at least five times.
Study NCT05973656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol dose given orally that will result in a 0.03% blood alcohol concentration (BAC).
Study NCT05973656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo saliva, mouthwash, and cheek brush collection
Study NCT05786586 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 650 nm low-level red-light
Description: 650 nm low-level red-light is a kind of laser, concentrated into a beam, to repeatedly irradiate the retina
Study NCT06330818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients will get special MRI sequences (CO2-triggered BOLD MRI, Vessel-wall imaging, resting state BOLD MRI) to identify cerebral vasoreactivity and disease activity.
Study NCT06330818 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: H2 15O PET/CT
Description: Patients will get H2 15O PET/CT with acetazolamide challenge to define the cerebral vasoreserve for comparison with fMRI Images
Study NCT06330818 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biosampling
Description: Patients do get a venous puncture for blood analysis on circulating endothelial cells and virus PCR analysis
Study NCT05468567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SPHERE protocol : Spatial hearing performances test
Description: Participants will be instructed to localize a sound emitted in their environment using a virtual reality setup (SPHEAR protocol).
Study NCT05468567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: French Matrix Test : audiology test of speech in noise perception
Description: Intelligibility threshold is the signal-to-noise ratio (in decibels) for which the subject can repeat 50% of the words heard in a dichotic listening.
Study NCT05468567 — intervention group
Intervention type: BEHAVIORAL
Intervention: SSQ15 questionnaire of life : (The Speech, Spatial and Other Qualities of Hearing Scale)
Description: The SSQ questionnaire is a clinical subjective scale that allows evaluating of hearing performances in daily life. The questionnaire is divided into 3 main items (A: speech; B: spatial hearing; C: other qualities of hearing) comprising questions with rating scores out of ten.
Study NCT05697640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vericiguat Oral Tablet
Description: The treatment period includes ten weeks of daily vericiguat or placebo intake (depending on randomization) and a 30-day follow-up period (no vericiguat/placebo intake).
Study NCT05697640 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vericiguat Oral Tablet
Description: The treatment period includes ten weeks of daily vericiguat or placebo intake (depending on randomization) and a 30-day follow-up period (no vericiguat/placebo intake).
Study NCT06581640 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T treatment
Description: Peripheral blood lymphocyte collection, PBMC separation, BCMA CAR-T cell preparation/storage, lymphodepletion chemotherapy pretreatment for the subject, and BCMA CAR-T cell infusion.
Study NCT05932459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension 100mg
Description: Take it with 240ml water in fasted condition.
Study NCT05932459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension 300mg
Description: Take it with water in fasted condition or after taking infant formula.
Study NCT05932459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide for Suspension 25mg
Description: Take it with 240ml water on an empty stomach.
Study NCT05932459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deuremidevir Hydrobromide tablets 100mg
Description: Take it with 240ml water in fasted condition.
Study NCT05962424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Ketamine is an FDA-approved dissociative anesthetic.
Study NCT05973656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo saliva, mouthwash, and cheek brush collection
Study NCT05973656 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breath Test
Description: Undergo breathalyzer testing
Study NCT05973656 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Breath Test
Description: Undergo breathalyzer testing
Study NCT04386239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab Prefilled Syringe
Description: Sarilumab administration must be associated with an antiviral treatment as defined by the treatment protocol suggested by the SIMET Experts group 4 and AIFA recommendations: chloroquine 500 mg 1 tablet twice daily or hydroxychloroquine 400 mg 1 tablet twice daily in the first day and then 200 mg 1 tablet twice daily.
Study NCT05247879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose containing Oral Rehydration Solution (ORS)
Description: Oral rehydration solution
Study NCT05247879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugar free - amino acid and electrolyte ORS
Description: Glucose free oral rehydration solution
Study NCT04994132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05716165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: proprioceptive knee braces
Description: The patient will perform the tests with the knee braces.
Study NCT05716165 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No knee brace
Description: The patient will perform the tests without the knee brace.
Study NCT06410443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Retention enema with 10mg dexamethasone, once a day, the total course of treatment for 1 week.
Study NCT06410443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics, probiotics, vitamins, antidiarrheal drugs, enteral nutrition, and endoscopic argon plasma coagulation
Description: Treatment according to guideline of radiation-induced intestinal injury.